Comparison of the Use of Enoxaparin Versus Unfractionated Heparin in Patients Undergoing Lower Extremity Revascularization

Abstract

Present available studies suggest that heparin prevents early vessel thrombosis in the immediate postoperative (POP) period after lower extremity bypass. Long-term anticoagulation with warfarin has also been used in these patients, based on its beneficial effect in preventing long-term graft failure. To compare the effectiveness between unfractionated heparin (UH) and low-molecular-weight heparin (enoxaparin) when used as transitional therapeutic POP anticoagulant therapy, a prospective study was performed. Seventy consecutive patients undergoing lower extremity bypass were studied. The initial 35 patients were started on a drip of UH 6 hours POP. The next 35 consecutive patients were treated with enoxaparin, the first dose starting 6 hours POP. All patients underwent subsequent anticoagulation with oral warfarin. There were no statistically significant differences between the two groups with regard to demographics, percentage of above/below the knee bypasses, type of conduit used, emergency operations, and overall complications. There was a significant difference in the length of stay (p = 0.05) in favor of the enoxaparin group, which also reflected a decreased overall cost in this group. In conclusion, POP anticoagulation with enoxaparin is as safe end effective as UH in patients undergoing lower extremity revascularization. Enoxaparin was associated with a decreased overall length of stay and hospital costs.

Get full access to this article

View all access options for this article.

References

1. Kraiss LW , Johansen K : Pharmacologic intervention to prevent graft failure. Surg Clin North Am 75:761-772, 1995.

2. Swedenborg J , Nydahl S , Egberg N : Low molecular mass heparin instead of unfractionated heparin during infrainguinal bypass surgery. Eur J Vasc Endovasc Surg 11:59-64, 1996.

3. Edmondson RA , Cohen AT , Das SK , et al: Low molecular weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 344:914-918, 1994.

4. McMillan WD , McCarthy WJ , Lin SJ , et al: Perioperative low molecular weight heparin for infrageniculate bypass. J Vasc Surg 25:796-802, 1997.

5. Hirsch J , Levine MN : Low molecular weight heparin. Blood 79:1-17, 1992.

6. Samama MM , Bara L , Gerotziafas GT : Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 24:105-117, 1994.

7. Jackson MR , Clagett GP : Antithrombotic therapy in peripheral arterial occlusive disease. Chest 114:666S-682S, 1998.

8. Rutherford RB , Jones DN , Bergentz S-E , et al: The efficacy of dextran 40 in preventing early postoperative thrombosis following difficult lower extremity bypass. J Vasc Surg 1:765-773, 1984.

9. Antiplatelet Trialists' Collaboration : Collaborative overview of randomized trials of antiplatelet treatment: Part II. Maintenance of vascular graft or arterial patency. Br Med J 308:159-168, 1994.

10.

10. McCollum C , Alexander C , Kenchington G , et al: Antiplatelet drugs in femoropopliteal vein bypasses: A multicenter trial. J Vasc Surg 13:150-162, 1991.

11.

11. Satiani B : A prospective randomized trial of aspirin in femoral popliteal and tibial bypass grafts. Angiology 36:608-616, 1985.

12.

12. Tangelder MJD , Lawson JA , Algra A , et al: Systematic review of randomized controlled trials of aspirin and oral anticoagulants in the prevention of graft occlusion and ischemic events after infrainguinal bypass surgery. J Vasc Surg 30:701-709, 1999.

13.

13. Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group : Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery: A randomised trial. Lancet 355:346-351, 2000.

14.

14. Schweiger H , Klein P , Ruf S , et al: Avoiding early failure of tibial prosthetic bypass grafts. Thorac Cardiovasc Surg 2:148-150, 1987.

15.

15. Wakefield TW , Lindblad B , Stanley TJ , et al: Heparin and protamine use in peripheral vascular surgery: A comparison between surgeons of the Society of Vascular Surgery and the European Society for Vascular Surgery. Eur J Vasc Surg 8:193-198, 1994.

16.

16. Schweiger H , Klein P , Ruf S , et al: Avoiding early failure of tibial prosthetic bypass grafts. Thorac Cardiovasc Surg 2:148-150, 1987.

17.

17. Samama CM , Gigou F , Ill P : Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: A multicenter open randomized study. Ann Vasc Surg 9(suppl):s45-s53, 1995.

18.

18. Kretschmer G , Herbst F , Prager M , et al: A decade of oral anticoagulant treatment to maintain autologous vein grafts for femoropopliteal atherosclerosis. Arch Surg 127:1112-1115, 1992.

19.

19. Kretschmer G , Wenzl E , Wagner O , et al: Influence of anticoagulant treatment in preventing graft occlusion following saphenous vein bypass for femoropopliteal occlusive disease. Br J Surg 73:689-692, 1986.

20.

20. Kretschmer G , Wenzl E , Piza F , et al: The influence of anticoagulant treatment on the probability of function in femoropopliteal vein bypass surgery: Analysis of a clinical series (1970 to 1985) and interim evaluation of a controlled clinical trial. Surgery 102:453-459, 1987.

21.

21. Arfvidsson B . Lundgren F , Drott C , et al: Influence of coumarin treatment on patency and limb salvage after peripheral arterial reconstructive surgery. Am J Surg 159:556-560, 1990.

22.

22. Clowes AW , Clowes MM : Kinetics of cellular proliferation after arterial injury. Heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res 58:839-845, 1986.

23.

23. Clowes AW , Karnowsky MJ : Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 265:625-626, 1977.

24.

24. Wilson NV , Salisbury JR , Kakkar WV : The effect of low molecular weight heparin on intimal hyperplasia in vein grafts. Eur J Vasc Surg 8:60-64, 1994.

25.

25. Hirsch J . Warkentin TE , Raschke R , et al: Heparin and low-molecular-weight heparin. Chest 114:s489-s510, 1998.

26.

26. Bergan JJ : Deep venous thrombosis. In: Current Surgical Therapy, 6th ed., ed. by Cameron JL . St Louis: Mosby, 1998, pp 885-903.

27.

27. Bara L , Billaud E , Gramond G . et al: Comparative pharmacokinetics of a low molecular weight heparin (PK1O 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 39:631-636, 1985.

28.

28. Warkentin TE , Levine MN , Hirsh J , et al: Heparininduced thrombocytopenia in patients treated with low-molecular-weight heparin of unfractionated heparin. N Engl J Med 332:1330-1335, 1995.

29.

29. Razuk A , Coimbra R. , Karakhanian W , et al: Femoral neuropathy secondary to nontraumatic retroperitoneal hemorrhage following intravenous heparin therapy: A case report. J Vascular Surg 34:87-90, 2000.

30.

30. Cohen M , Demers C , Gurfinkel EP , et al: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 337:447-452, 1997.

31.

31. Levine M , Gent M , Hirsh J , et al: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677-681, 1996.

32.

32. Lindblad B , Wakefield TW , Stanley TJ , et al: Pharmacological prophylaxis against postoperative graft occlusion after peripheral vascular surgery: A world-wide survey. Eur J Vasc Endovasc Surg 9:267-271, 1995.